# Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®

> **NCT04115488** · PHASE3 · COMPLETED · sponsor: **Polpharma Biologics S.A.** · enrollment: 265 (actual)

## Conditions studied

- Relapsing-Remitting Multiple Sclerosis (RRMS)

## Interventions

- **BIOLOGICAL:** Intravenous (IV) infusions

## Key facts

- **NCT ID:** NCT04115488
- **Lead sponsor:** Polpharma Biologics S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-01
- **Primary completion:** 2021-08-23
- **Final completion:** 2022-02-07
- **Target enrollment:** 265 (ACTUAL)
- **Last updated:** 2023-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04115488

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04115488, "Efficacy and Safety of the Biosimilar Natalizumab PB006 in Comparison to Tysabri®". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04115488. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*